RECORDATI

NEWS RELEASE

RECORDATI: PUBLIC DISCLOSURE COMPLIANCE

Milan, 3rd May 2019 – Please be informed that the minutes of the Ordinary Shareholders' Meeting held on 11 April 2019 are available at the Company's registered office, on the Company's website (www.recordati.com; section Investors, Shareholders' Meetings) as well as on the "1info" storage mechanism (www.1info.it).

Recordati, established in 1926, is an international pharmaceutical group, listed on the Italian Stock Exchange (Reuters RECI.MI, Bloomberg REC IM, ISIN IT 0003828271), with a total staff of more than 4,100, dedicated to the research, development, manufacturing and marketing of pharmaceuticals. Headquartered in Milan, Italy, Recordati has operations throughout the whole of Europe, including Russia, Turkey, North Africa, the United States of America, Canada, Mexico, some South American countries, Japan and Australia. An efficient field force of medical representatives promotes a wide range of innovative pharmaceuticals, both proprietary and under license, in a number of therapeutic areas including a specialized business dedicated to treatments for rare diseases. Recordati is a partner of choice for new product licenses for its territories. Recordati is committed to the research and development of new specialties with a focus on treatments for rare diseases. Consolidated revenue for 2018 was € 1,352.2 million, operating income was € 442.2 million and net income was € 312.4 million.

Media Relations

Studio Noris Morano

For further information:

Recordati website: www.recordati.com

<u>Investor Relations</u>
Marianne Tatschke

(39)0248787393 (39)0276004736, (39)0276004745

e-mail: investorelations@recordati.it e-mail: norismorano@studionorismorano.com